Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UV 1

Next Previous
Drug Profile

UV 1

Alternative Names: UV-1; UV1 synthetic peptide vaccine; UV1 vaccine

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norwegian Radium Hospital; Ultimovacs AS
  • Developer Arbeitsgemeinschaft Internistische Onkologie; AstraZeneca; Bristol-Myers Squibb; European Network of Gynaecological Oncological Trial Groups; Hellenic Cooperative Oncology Group; Nordic Society of Gynaecological - Clinical Trial Unit; North Eastern German Society of Gynaecological Oncology; Oslo University Hospital; Ultimovacs AS; Vestre Viken Hospital Trust; Working Group for Gynecological Oncology; Zelluna ASA
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer; Squamous cell cancer
  • Phase I/II Prostate cancer

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Metastatic disease) in USA (Intradermal, Injection)
  • 13 Sep 2024 Efficacy data from a phase II NIPU trial in Malignant mesothelioma presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 05 Aug 2024 Phase-II clinical trials in Squamous cell cancer (Second-line therapy or greater, Adjuvant therapy, Metastatic disease, Inoperable/Unresectable) in Germany (Intradermal) (NCT05075122)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top